Navigation Links
Neurocrine Biosciences Reports Third Quarter 2008 Results
Date:10/28/2008

is symptoms using several different scales for endometriosis pain. The 6-month results from this study, together with data from the other Phase II studies, will be the basis for securing agreement on a registration plan with the Food and Drug Administration (FDA).

The Company is also currently conducting two additional randomized placebo-controlled Phase II clinical trials. The clinical endpoints for both of these trials are a reduction in pelvic pain associated with endometriosis, utilizing a scale proposed by the FDA. The first Phase II trial includes our selected commercial formulation tablet in two doses, (150 mg and 250 mg); this trial has completed randomization in 155 patients. The Company expects topline results from the first three months of treatment in the first quarter of 2009. The second trial is a four arm comparator trial of two doses of elagolix (150 mg and 250 mg), placebo or leuprolide depot. This trial is being conducted in Central and Eastern Europe. Topline data from this 3-month double-blind trial of approximately 180 patients should be available at the end of the first half of 2009.

Neurocrine is also investigating the potential of certain GnRH antagonists in treating other hormone-dependent diseases in Men's and Women's Health.

Corticotropin Releasing Factor (CRF1) Receptor Antagonists for Anxiety/Depression and IBS

The CRF collaboration between Neurocrine and GSK has identified multiple unique high affinity and selective antagonists for the CRF1 receptor that are currently in clinical development for mood disorders and irritable bowel syndrome (IBS). There are currently three distinct CRF compounds in clinical development that have arisen out of the GSK collaboration. The compound (876008) is in a Phase II "proof of concept" trial to evaluate its safety and efficacy in patients with IBS. Approximately 130 patients meeting established diagnostic criteria for IBS have been entered into this cross-over design trial.
'/>"/>

SOURCE Neurocrine Biosciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Webcast Alert: Neurocrine Announces 3Q 08 Financial Results
2. Neurocrine Biosciences to Present at the Oppenheimer 19th Annual Healthcare Conference
3. Neurocrine Biosciences Announces Conference Call and Webcast to Present Third Quarter 2008 Financial Results
4. Neurocrine Biosciences to Present at the UBS Global Life Sciences Conference
5. Neurocrine Biosciences to Present at Thomas Weisel Healthcare Conference and the NewsMakers in the Biotech Industry Conference
6. Neurocrine Biosciences Reports Second Quarter 2008 Results
7. Neurocrine Biosciences Announces Conference Call and Webcast To Present Second Quarter 2008 Financial Results
8. Neurocrine Biosciences to Present at the 2008 Citi Investment Research Global Health Care Conference
9. Neurocrine Biosciences Announces Conference Call and Webcast to Present First Quarter 2008 Financial Results
10. Neurocrine Biosciences Announces Conference Call and Webcast to Present Fourth Quarter and Year End 2007 Financial Results
11. Neurocrine Announces Appointment of Kevin Gorman, Ph.D., as President and Chief Executive Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... MA (PRWEB) December 18, 2014 Reports ... in the United States suffer from one or more ... asthma, or cancer. Medication can address some of these ... daily activities that many sufferers face. While implanted nerve ... and stimulate the whole nerve, which can induce side ...
(Date:12/19/2014)... With only 2 weeks left of ... Sartorius Biohit products . The product specials include Buy ... Pipette Trade-in Program, and free pipette tips. , Sartorius ... the world. They are ideal for lab technicians performing ... ,     Full volume range of 0.1 uL to ...
(Date:12/19/2014)... , Dec. 18, 2014 Relmada Therapeutics, Inc. ... the treatment of chronic pain, announced the results of ... "This was a transformational year in Relmada,s history ... for our company," said Sergio Traversa , chief ... have executed on key financial, human resource and clinical ...
(Date:12/17/2014)... 2014 Achim Noack has been named ... Group. In this position, Noack will assist Jerry Stoller, ... develop marketing strategy and supervise global marketing management and ... has tremendous knowledge and experience in the crop protection ... experience and innovative thinking will be a great asset ...
Breaking Biology Technology:Draper Wins GSK Funding for Smaller, Smarter Implantable Devices 2Major Pipette Distributor Pipette.com Announces Sartorius Year End Specials 2Relmada Therapeutics Announces Results of Annual Shareholders Meeting 2Achim Noack Joins Stoller Group as Global Vice President of Marketing and Administration 2
... LEXINGTON, Mass., Sept. 29 RainDance,Technologies announced ... a,research initiative conducted with sanofi-aventis, Paris (EURONEXT: ... of Strasbourg, France, to develop,the next generation ... The consortium was founded with the assistance ...
... Sept. 29 diaDexus, Inc.,today announced its partnership ... dedicated to combating cardiovascular disease in,current and retired ... as part,of the LHF,s cardiovascular risk assessment and ... risk for suffering a heart,attack or stroke., ...
... Poniard,Pharmaceuticals, Inc. (Nasdaq: PARD ), a biopharmaceutical ... chairman and CEO,will present at the JMP Securities Healthcare ... Time at Le Parker Meridien in New York., ... discussion,of the development of picoplatin, the Company,s lead product ...
Cached Biology Technology:RainDance Technologies Signs a Collaboration Agreement with sanofi-aventis and Louis Pasteur University to Launch dScreen Consortium within ALSACE BIOVALLEY cluster 2RainDance Technologies Signs a Collaboration Agreement with sanofi-aventis and Louis Pasteur University to Launch dScreen Consortium within ALSACE BIOVALLEY cluster 3RainDance Technologies Signs a Collaboration Agreement with sanofi-aventis and Louis Pasteur University to Launch dScreen Consortium within ALSACE BIOVALLEY cluster 4RainDance Technologies Signs a Collaboration Agreement with sanofi-aventis and Louis Pasteur University to Launch dScreen Consortium within ALSACE BIOVALLEY cluster 5diaDexus, Inc. and Living Heart Foundation Offer the PLAC(R) Test to Detect Hidden Risk for Heart Attack and Stroke in Retired NFL Players 2Poniard Pharmaceuticals to Present at the JMP Securities Healthcare Focus Conference 2
(Date:12/5/2014)... 4, 2014  Tute Genomics, a leader in cloud-based ... Series A1 funding led by UK-based Eurovestech. Peak Ventures ... the investment round. "We are at a ... next-generation sequencing and seeks new approaches for the diagnosis, ... , MD MBA, and CEO of Tute Genomics. "One ...
(Date:12/3/2014)... , Dec. 2, 2014   Marvin Test ... innovative test solutions for military, aerospace, and manufacturing ... of its successful TS-900 PXI semiconductor test ... features of high-end systems to customers at a ... compared to traditional ATE. "Our ...
(Date:11/21/2014)... -- According to a new market research ... Access Control, Intrusion Detection, Parking Management, Under Vehicle Inspection), ... Geography - Global Forecasts to 2020", published by MarketsandMarkets, ... around $25 Billion in 2014 and is expected to ... of 8.69%. Browse 116 market data Tables ...
Breaking Biology News(10 mins):Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 2Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 3Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 2Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 3Industrial Security Systems Market Worth $38 Billion by 2020 2Industrial Security Systems Market Worth $38 Billion by 2020 3
... November 13, 2012Following an infection, dysregulation of the immune ... an often fatal condition called severe sepsis or septic ... underlying immune dysfunction remain poorly understood. Regulatory T cells ... to have an important role in suppressing the immune ...
... some glaciers of the Himalayas will continue shrinking for ... Young University geology professor Summer Rupper comes after her ... the monsoonal Himalayas. Published in Geophysical Research Letters ... climate remained steady, almost 10 percent of Bhutan,s glaciers ...
... PHILADELPHIA Passing one,s genes on to the next generation ... that the body would work to ensure that the genes ... New research by biologists at the University of ... the body does exactly that. This protective role is fulfilled ...
Cached Biology News:Are we closer to understanding the cause of deadly sepsis? 2Himalayan glaciers will shrink even if temperatures hold steady 2A class of RNA molecules protects germ cells from damage, Penn vet researchers show 2A class of RNA molecules protects germ cells from damage, Penn vet researchers show 3
... is formuatled for the growth of ... Sf21 cells. Grace's Insect Mediu, Unsupplemented ... does not contain lactalbumin hydrosylate, and ... Grace's Insect Medium, Supplemented is formulated ...
D.R. Harper (1993) • Includes: essential information on taxonomy, culture and safe handling of viruses, immunology, monoclonal antibodies, antivirals and vaccines....
...
... PCR Purification Kits provide rapid and efficient ... PCR products, and salts from PCR products ... provides two Binding Buffer options for ... can be performed in either single column ...
Biology Products: